Stan Gill

687 total citations
13 papers, 150 citations indexed

About

Stan Gill is a scholar working on Oncology, Infectious Diseases and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Stan Gill has authored 13 papers receiving a total of 150 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 4 papers in Infectious Diseases and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Stan Gill's work include Colorectal Cancer Treatments and Studies (4 papers), Acute Myeloid Leukemia Research (2 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Stan Gill is often cited by papers focused on Colorectal Cancer Treatments and Studies (4 papers), Acute Myeloid Leukemia Research (2 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Stan Gill collaborates with scholars based in United States, Canada and United Kingdom. Stan Gill's co-authors include Yves Humblet, Jan Cosaert, Malcolm J. Moore, Jaafar Bennouna, Aijing Shang, Chris Verslype, Eric Van Cutsem, Walter L. Vervenne, Jean‐Luc Van Laethem and Patrick Schöffski and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Journal of Hepatology.

In The Last Decade

Stan Gill

13 papers receiving 146 citations

Peers

Countries citing papers authored by Stan Gill

Since Specialization

Citations

This map shows the geographic impact of Stan Gill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stan Gill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stan Gill more than expected).

Fields of papers citing papers by Stan Gill

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stan Gill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stan Gill. The network helps show where Stan Gill may publish in the future.

Co-authorship network of co-authors of Stan Gill

This figure shows the co-authorship network connecting the top 25 collaborators of Stan Gill. A scholar is included among the top collaborators of Stan Gill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stan Gill. Stan Gill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study 2016 ·Journal of Neuro-Oncology ·Regina I. Jakacki, Margaret A. Foley, Julie D. Horan, Jiuzhou Wang, Mark W. Kieran, Daniel C. Bowers, Éric Bouffet, Stergios Zacharoulis, Stan Gill	20
2	Pharmacokinetics and pharmacodynamics of gilteritinib in patients with relapsed or refractory acute myeloid leukemia. 2016 ·Journal of Clinical Oncology ·Catherine C. Smith, Mark J. Levis, Mark R. Litzow, Alexander E. Perl, Jessica K. Altman, Stan Gill, Geoffrey J. Yuen, Peter L. Bonate, Takeshi Kadokura, (unknown), Charles Y. Liu, Itsuro Nagase, (unknown), Erkut Bahceci	5
3	Results of a first-in-human, phase I/II trial of ASP2215, a selective, potent inhibitor of FLT3/Axl in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). 2015 ·Journal of Clinical Oncology ·Mark J. Levis, Alexander E. Perl, Jessica K. Altman, Jörge E. Cortes, Ellen K. Ritchie, Richard A. Larson, Catherine C. Smith, Eunice S. Wang, Stephen A. Strickland, Maria R. Baer, Mark R. Litzow, David F. Claxton, Gary J. Schiller, Celalettin Üstün, Charles Y. Liu, Stan Gill, (unknown), Erkut Bahceci	30
4	Common and rare EGFR mutations (EGFRm) in the RADIANT trial: Final follow-up with 5 year data. 2015 ·Journal of Clinical Oncology ·Frances A. Shepherd, Wilfried Eberhardt, Nasser K. Altorki, Mary O’Brien, Joe Wang, (unknown), Stan Gill, Kenneth K. Iwata, Frank C. Richardson, Julie D. Horan, Margaret A. Foley, Karen Kelly	3
5	Factors associated with delayed time to adjuvant chemotherapy (AC) in stage III colon cancer: British Columbia Cancer Agency (BCCA) cohort experience. 2011 ·Journal of Clinical Oncology ·Arlene Chan, Rodney Woods, Stan Gill	1
6	Juvenile toxicity study of faropenem medoxomil in beagle puppies 2010 ·Reproductive Toxicology ·Ali S. Faqi, (unknown), Stan Gill, Dorothy B. Colagiovanni	2
7	An intranasal irritation assessment of antibacterial ointment alone or in combination with mupirocin versus Bactroban Nasal® in rabbits 2009 ·Regulatory Toxicology and Pharmacology ·Ali S. Faqi, Stacie Bell, Stan Gill, Dorothy B. Colagiovanni	2
8	Analysis of prognostic (prog) Web-based models for stage II and III colon cancer (CC): A population-based validation of Numeracy (NUM) and ADJUVANT! Online (ADJ!) 2009 ·Journal of Clinical Oncology ·Stan Gill, Charles L. Loprinzi, Hagen Kennecke, Axel Grothey, Garth D. Nelson, (unknown), (unknown), (unknown), Aditya Bardia, Daniel J. Sargent	1
9	A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer 2008 ·Journal of Clinical Oncology ·Walter L. Vervenne, Jaafar Bennouna, Yves Humblet, Stan Gill, Malcolm J. Moore, Jean‐Luc Van Laethem, Aijing Shang, Jan Cosaert, Chris Verslype, Eric Van Cutsem	38
10	Phase I Study of OSI-7904L, a Novel Liposomal Thymidylate Synthase Inhibitor in Patients with Refractory Solid Tumors 2005 ·Clinical Cancer Research ·Gernot Beutel, Hilary Glen, Patrick Schöffski, (unknown), Stan Gill, James T. Cassidy, Chris Twelves	20
11	Adefovir dipivoxil safety and pharmacokinetics in subjects with hepatitis B virus infection and in healthy subjects 2002 ·Journal of Hepatology ·Brian P. Kearney, W B Knight, Graeme Currie, (unknown), Ramin Ebrahimi, Stan Gill, John Fry, Carol Brosgart	6
12	A drug-drug interaction study between adefovir dipivoxil and lamivudine, acetaminophen, ibuprofen and trimethoprim/sulfamethoxazole 2002 ·Journal of Hepatology ·Brian P. Kearney, W B Knight, Graeme Currie, (unknown), John E. Wolf, Stan Gill, (unknown), Carol Brosgart	5
13	Dosing guidelines for Adefovir Dipivoxil in the treatment of HBV infected patients with renal or hepatic impairment 2002 ·Journal of Hepatology ·W B Knight, (unknown), Yves Benhamou, Graeme Currie, Ramin Ebrahimi, Stan Gill, John Fry, Brian P. Kearney, Carol Brosgart	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact